Helius Medical Technologies Inc Class A Stock

$0.21

37.92% yesterday

Nasdaq, Jun 27, 10:16 pm CET

ISIN

US42328V5049

Symbol

HSDT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Helius Medical Technologies Inc Class A Stock price

$0.21

-11,051.04 100.00% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.13 37.92%

ISIN

US42328V5049

Symbol

HSDT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$110.0k

Enterprise Value

$-1.0m

Net debt

$-1.1m

Cash

$1.1m

Shares outstanding

410.0k

Valuation (TTM | estimate)

P/E

negative | negative

P/S

0.26 | 0.29

EV/Sales

negative | negative

EV/FCF

0.09

P/B

0.07

Financial Health

Equity Ratio

29.90%

Return on Equity

-1,108.78%

ROCE

-979.59%

ROIC

-1,367.74%

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$430.0k | $381.5k

EBITDA

$-14.5m | -

EBIT

$-14.5m

Net Income

$-13.1m | $-4.0m

Free Cash Flow

$-11.6m

Growth (TTM | estimate)

Revenue

4.88% | -26.63%

EBITDA

-65.11% | -

EBIT

-64.47%

Net Income

-80.89% | 65.84%

Free Cash Flow

-819.05%

Margin (TTM | estimate)

Gross

-33.64%

EBITDA

-3,336.64% | -

EBIT

-3,340.55%

Net

-3,010.14% | -1,052.41%

Free Cash Flow

-2,667.28%

EPS

$-25.93

FCF per Share

$-28.23

Short interest

74.02%

Employees

21.00

Rev per Employee

$20.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Helius Medical Technologies Inc Class A Stock Analysis

Unlock Scores for Free

??

6 Analysts have issued a Helius Medical Technologies Inc Class A forecast:

3x Hold

50%

3x Sell

50%

More details on Analyst Estimates Including Price Targets

6 Analysts have issued a Helius Medical Technologies Inc Class A forecast:

Hold

50%

Sell

50%

Analyst Estimates with Stock Price Targets

Financial data from Helius Medical Technologies Inc Class A

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	0.43 0.43	5% 5% 100%
- Direct Costs	0.58 0.58	45% 45% 135%
Gross Profit	-0.15 -0.15	1,600% 1,600% -35%
- Selling and Administrative Expenses	10 10	62% 62% 2,437%
- Research and Development Expense	3.82 3.82	77% 77% 888%
EBITDA	-14 -14	65% 65% -3,367%
- Depreciation and Amortization	0.02 0.02	60% 60% 5%
EBIT (Operating Income) EBIT	-14 -14	64% 64% -3,372%
Net Profit	-13 -13	81% 81% -3,037%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Helius Medical Technologies Inc Class A Stock News

Neutral

GlobeNewsWire

●

about 20 hours ago

Helius Medical Technologies Announces Reverse Stock Split

NEWTOWN, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-50 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time on June 30, 202...

Neutral

GlobeNewsWire

●

12 days ago

Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device

- CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19,160- NEWTOWN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurote...

Neutral

GlobeNewsWire

●

16 days ago

Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting

-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis-

More Helius Medical Technologies Inc Class A News

Company Profile

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain's ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.

Head office	United States
CEO	Dane Andreeff
Employees	21
Founded	2014
Website	heliusmedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now